[1]´Þ³¯³õ,¬¡¡ÄÈ,·ë³¬Àö,µÈ.Ç°µ°°×ת»¯Ã¸¿Ý²Ý¸Ë¾úµ°°×ø9¼°ÆäÒÖÖƼÁÔÚ¶¯ÂöÖàÑùÓ²»¯ÖеÄ×÷ÓÃÑо¿½øÕ¹[J].ÐÂÏçҽѧԺѧ±¨,2021,38(3):213-219.[doi:10.7683/xxyxyxb.2021.03.003]

µã»÷¸´ÖÆ

Ç°µ°°×ת»¯Ã¸¿Ý²Ý¸Ë¾úµ°°×ø9¼°ÆäÒÖÖƼÁÔÚ¶¯ÂöÖàÑùÓ²»¯ÖеÄ×÷ÓÃÑо¿½øÕ¹

·ÖÏíµ½£º

²Î¿¼ÎÄÏ×/References:

£Û1£Ý¡¡KOBIYAMA K,LEY K.Atherosclerosis£ÛJ£Ý.Circ Res,2018,123(10):1118-1120.
£Û2£Ý¡¡¹ùȨ,ÕÔ¹ú°²,ÁÖ·É,µÈ,ºÓÄϱ±²¿ÈËȺѪ֬ÄêÁä³Ë»ýÓë¹Ú×´¶¯ÂöÖàÑùÓ²»¯ÐÔÐÄÔಡµÄÏà¹ØÐÔ£ÛJ£Ý.ÐÂÏçҽѧԺѧ±¨,2020,37(8):734-738.
£Û3£Ý¡¡SABATINE M S,GIUGLIANO R P,KEECH A C,et al.Evolo-cumab and clinical outcomes in patients with cardiovascular disease£ÛJ£Ý.N Engl J Med,2017,376(18):1713-1722.
£Û4£Ý¡¡ZAID A,ROUBTSOVA A,ESSALMANI R,et al.Proprotein conver-tase subtilisin/kexin type 9 (PCSK9):hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration£ÛJ£Ý.Hepatology,2008,48(2):646-654.
£Û5£Ý¡¡DING Z,LIU S,WANG X,et al.Cross-talk between LOX-1 and PCSK9 in vascular tissues£ÛJ£Ý.Cardiovasc Res,2015,107(4):556-567.
£Û6£Ý¡¡DESAI N R,GIUGLIANO R P,ZHOU J,et al.AMG 145,a monoclonal antibody against PCSK9,facilitates achievement of national cholesterol education program-adult treatment panel ¢ó low-density lipoprotein cholesterol goals among high-risk patients:an analysis from the LAPLACE-TIMI 57 trial (LDL-c assessment with PCSK9 monoclonal antibody inhibition combined with statin therapy-thrombolysis in myocardial infarction 57)£ÛJ£Ý.J Am Coll Cardiol,2014,63(5):430-433.
£Û7£Ý¡¡SABNIS R W.Novel cyclic tetramer compounds as PCSK9 inhibitors for treating metabolic disorders£ÛJ£Ý.ACS Med Chem Lett,2020,11(9):1671-1673.
£Û8£Ý¡¡KADDOURA R,ORABI B,SALAM A M.PCSK9 monoclonal antibodies:an overview£ÛJ£Ý.Heart Views,2020,21(2):97-103.
£Û9£Ý¡¡FITZGERALD K,WHITE S,BORODOVSKY A,et al.A highly durable RNAi therapeutic inhibitor of PCSK9£ÛJ£Ý.N Engl J Med,2017,376(1):41-51.
£Û10£Ý¡¡CATAPANO A L,PIRILLO A,NORATA G D.New pharmacological approaches to target PCSK9£ÛJ£Ý.Curr Atheroscler Rep,2020,22(7):24.
£Û11£Ý¡¡Àî¹óçù,ÖÜÓñÑô,·¨Ïܶ÷,µÈ.ÂÈÀ×Ëû¶¨¶ÔÑõ»¯Ð͵ÍÃܶÈÖ¬µ°°×ÓÕµ¼ÈËѪ¹ÜÄÚƤϸ°û𤸽ºÍÑ×Ö¢·´Ó¦µÄÓ°Ïì£ÛJ£Ý.ÐÂÏçҽѧԺѧ±¨,2020,37(7):606-610.
£Û12£Ý¡¡ZHANG C,YE L,ZHANG Q,et al.The role of TRPV1 channels in atherosclerosis£ÛJ£Ý.Channels (Austin),2020,14(1):141-150.
£Û13£Ý¡¡HASSANPOUR M,RAHBARGHAZI R,NOURI M,et al.Role of autophagy in atherosclerosis:foe or friend£ÛJ£Ý.J Inflamm (Lond),2019,16:8.
£Û14£Ý¡¡COLLINS R,REITH C,EMBERSON J,et al.Interpretation of the evidence for the efficacy and safety of statin therapy£ÛJ£Ý.Lancet,2016,388(10059):2532-2561.
£Û15£Ý¡¡MUNDI S,MASSARO M,SCODITTI E,et al.Endothelial permeability,LDL deposition,and cardiovascular risk factors-a review£ÛJ£Ý.Cardiovasc Res,2018,114(1):35-52.
£Û16£Ý¡¡COLL R C,ROBERTSON A A,CHAE J J,et al.A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases£ÛJ£Ý.Nat Med,2015,21(3):248-255.
£Û17£Ý¡¡SAGE A P,MALLAT Z.Readapting the adaptive immune response-therapeutic strategies for atherosclerosis£ÛJ£Ý.Br J Pharmacol,2017,174(22):3926-3939.
£Û18£Ý¡¡PARK S,LEE I K.Progression of multifaceted immune cells in atherosclerotic development£ÛJ£Ý.J Lipid Atheroscler,2019,8(1):15-25.
£Û19£Ý¡¡ABIFADEL M,VARRET M,RAB¦KS J P,et al.Mutations in PCSK9 cause autosomal dominant hypercholesterolemia£ÛJ£Ý.Nat Genet,2003,34(2):154-156.
£Û20£Ý¡¡ROSENSON R S,HEGELE R A,FAZIO S,et al.The evolving future of PCSK9 inhibitors£ÛJ£Ý.J Am Coll Cardiol,2018,72(3):314-329.
£Û21£Ý¡¡DING Z,LIU S,WANG X,et al.Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta£ÛJ£Ý.Antioxid Redox Signal,2015,22(9):760-771.
£Û22£Ý¡¡DING Z,WANG X,LIU S,et al.PCSK9 expression in the ischaemic heart and its relationship to infarct size,cardiac function,and development of autophagy£ÛJ£Ý.Cardiovasc Res,2018,114(13):1738-1751.
£Û23£Ý¡¡ADORNI M P,CIPOLLARI E,FAVARI E,et al.Inhibitory effect of PCSK9 on abca1 protein expression and cholesterol efflux in macrophages£ÛJ£Ý.Atherosclerosis,2017,256:1-6.
£Û24£Ý¡¡Ð¤ÎÄ»¢,Õźì,ÅíÏæƼ£¬µÈ.PCSK9½á¹¹Ó빦ÄÜ£ÛJ£Ý.ÖйúÉúÎﻯѧÓë·Ö×ÓÉúÎïѧ±¨,2009,25(3):213-218.
£Û25£Ý¡¡LIU X,BAO X,HU M,et al.Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer£ÛJ£Ý.Nature,2020,588(7839):693-698.
£Û26£Ý¡¡DING Z,LIU S,WANG X,et al.Cross-talk between PCSK9 and damaged mtdna in vascular smooth muscle cells:role in apoptosis£ÛJ£Ý.Antioxid Redox Signal,2016,25(18):997-1008.
£Û27£Ý¡¡RUSCICA M,RICCI C,MACCHI C,et al.Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9(PCSK9) expression in hepatic HepG2 cell line£ÛJ£Ý.J Biol Chem,2016,291(7):3508-3519.
£Û28£Ý¡¡DONG J,HE M,LI J,et al.Microrna-483 ameliorates hypercho-lesterolemia by inhibiting PCSK9 production£ÛJ£Ý.JCI Insight,2020,5(23):e143812.
£Û29£Ý¡¡COHEN J,PERTSEMLIDIS A,KOTOWSKI I K,et al.Low LDL cholesterol in individuals of african descent resulting from frequent nonsense mutations in PCSK9£ÛJ£Ý.Nat Genet,2005,37(2):161-165.
£Û30£Ý¡¡BEN DJOUDI OUADDA A,GAUTHIER M S,SUSAN-RESIGA D,et al.Ser-phosphorylation of PCSK9 (proprotein convertase subtilisin-kexin 9) by Fam20C (family with sequence similarity 20,member c) kinase enhances its ability to degrade the LDLR (low-density lipoprotein receptor)£ÛJ£Ý.Arterioscler Thromb Vasc Biol,2019,39(10):1996-2013.
£Û31£Ý¡¡GUSTAFSEN C,OLSEN D,VILSTRUP J,et al.Heparan sulfate proteoglycans present PCSK9 to the LDL receptor£ÛJ£Ý.Nat Commun,2017,8(1):503.
£Û32£Ý¡¡OLEAGA C,HAY J,GURCAN E,et al.Insights on the kinetics and dynamics of the furin-cleaved form of PCSK9£ÛJ£Ý.J Lipid Res,2020,62:100003.
£Û33£Ý¡¡MELENDEZ Q M,WOOTEN C J,KRISHNAJI S T,et al.Identification of novel proteins interacting with proprotein convertase subtilisin/kexin 9£ÛJ£Ý.Int J Biomed Investig,2020,3(1):1-17.
£Û34£Ý¡¡JANG H D,LEE S E,YANG J,et al.Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9£ÛJ£Ý.Eur Heart J,2020,41(2):239-252.
£Û35£Ý¡¡SCHIELE F,PARK J,REDEMANN N,et al.An antibody against the c-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo£ÛJ£Ý.J Mol Biol,2014,426(4):843-852.
£Û36£Ý¡¡KASTELEIN J.Targeting PCSK9:expanding knowledge and targeting new frontiers.Paris:ESC Congress,2019£ÛEB/OL£Ý.£Û2019-09-09£Ý.https://pace-cme.org/2019/09/09/slides-targeting-pcsk9-expanding-knowledge-and-targeting-new-frontiers/download-slides-targeting-pcsk9-expanding-knowledge-and-targeting-new-frontiers.pdf.
£Û37£Ý¡¡RHAINDS D,ARSENAULT B J,TARDIF J C.PCSK9 inhibition and LDL cholesterol lowering:the biology of an attractive therapeutic target and critical review of the latest clinical trials£ÛJ£Ý.Clinical Lipidology,2012,7(6):621-640.
£Û38£Ý¡¡HAZEN S L.New lipid and lipoprotein targets for the treatment of cardiometabolic diseases£ÛJ£Ý.J Lipid Res,2012,53(9):1719-1721.
£Û39£Ý¡¡HUANG Y,NING K,LI W W,et al.Hydrogen sulfide accumulates LDL receptor precursor via downregulating PCSK9 in HepG2 cells£ÛJ£Ý.Am J Physiol Cell Physiol,2020£¬319£¨6£©£ºC1082-C1096.
£Û40£Ý¡¡NAVARESE E P,KOLODZIEJCZAK M,WINTER M P,et al.Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor:the PCSK9-react study£ÛJ£Ý.Int J Cardiol,2017,227:644-649.
£Û41£Ý¡¡HUO Y,SCHOBER A,FORLOW S B,et al.Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoproteine£ÛJ£Ý.Nat Med,2003,9(1):61-67.
£Û42£Ý¡¡CAMERA M,ROSSETTI L,BARBIERI S S,et al.PCSK9 as a positive modulator of platelet activation£ÛJ£Ý.J Am Coll Cardiol£¬2018,71(8):952-954.
£Û43£Ý¡¡DING Z,WANG X,SCHNACKENBERG L,et al.Regulation of autophagy and apoptosis in response to ox-LDL in vascular smooth muscle cells,and the modulatory effects of the microrna hsa-let-7 g£ÛJ£Ý.Int J Cardiol,2013,168(2):1378-1385.
£Û44£Ý¡¡DING Z,LIU S,WANG X,et al.PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages£ÛJ£Ý.Cardiovasc Res,2018,114(8):1145-1153.
£Û45£Ý¡¡DING Z,WANG X,LIU S,et al.NLRP3 inflammasome via IL-1 beta regulates PCSK9 secretion£ÛJ£Ý.Theranostics,2020,10(16):7100-7110.
£Û46£Ý¡¡GIUNZIONI I,TAVORI H,COVARRUBIAS R,et al.Local effects of human PCSK9 on the atherosclerotic lesion£ÛJ£Ý.J Pathol,2016,238(1):52-62.
£Û47£Ý¡¡SGRIGNANI J,FASSI E M A,LAMMI C,et al.Exploring proprotein convertase subtilisin/kexin 9 (PCSK9) autoproteolysis process by molecular simulations:hints for drug design£ÛJ£Ý.Chem Med Chem,2020,15(16):1601-1607.
£Û48£Ý¡¡KIRCHHOFER D,BURDICK D J,SKELTON N J,et al.Regions of conformational flexibility in the proprotein convertase PCSK9 and design of antagonists for LDL cholesterol lowering£ÛJ£Ý.Biochem Soc Trans,2020,48(4):1323-1336.
£Û49£Ý¡¡ABDELWAHED K S,SIDDIQUE A B,MOHYELDIN M M,et al.Pseurotin a as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor£ÛJ£Ý.Pharmacol Res,2020,158:104847.
£Û50£Ý¡¡LEVISETTI M,JOH T,WAN H,et al.A phase i randomized study of a specifically engineered,pH-sensitive PCSK9 inhibitor RN317 (pf-05335810) in hypercholesterolemic subjects on statin therapy£ÛJ£Ý.Clin Transl Sci£¬2017,10(1):3-11.
£Û51£Ý¡¡JAIN M,CARLSON G,COOK W,et al.Randomised,phase 1,dose-finding study of MEDI4166,a PCSK9 antibody and GLP-1 analogue fusion molecule,in overweight or obese patients with type 2 diabetes mellitus£ÛJ£Ý.Diabetologia,2019,62(3):373-386.
£Û52£Ý¡¡BARUCH A,MOSESOVA S,DAVIS J D,et al.Effects of RG7652,a monoclonal antibody against PCSK9,on LDL-c,LDL-c subfractions,and inflammatory biomarkers in patients at high risk of or with established coronary heart disease (from the phase 2 equator study)£ÛJ£Ý.Am J Cardiol,2017,119(10):1576-1583.
£Û53£Ý¡¡KASTELEIN J J,NISSEN S E,RADER D J,et al.Safety and efficacy of LY3015014,a monoclonal antibody to proprotein convertase subtilisin/kexin type 9(PCSK9):a randomized,placebo-controlled phase 2 study£ÛJ£Ý.Eur Heart J,2016,37(17):1360-1369.
£Û54£Ý¡¡RIDKER P M,TARDIF J C,AMARENCO P,et al.Lipid-reduction variability and antidrug-antibody formation with bococizumab£ÛJ£Ý.N Engl J Med,2017,376(16):1517-1526.
£Û55£Ý¡¡WEIDER E,SUSAN-RESIGA D,ESSALMANI R,et al.Proprotein convertase subtilisin/kexin type 9 (PCSK9) single domain antibodies are potent inhibitors of low density lipoprotein receptor degradation£ÛJ£Ý.J Biol Chem,2016,291(32):16659-16671.
£Û56£Ý¡¡ZHANG Y,EIGENBROT C,ZHOU L,et al.Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor£ÛJ£Ý.J Biol Chem,2014,289(2):942-955.
£Û57£Ý¡¡MASUDA Y,YAMAGUCHI S,SUZUKI C,et al.Generation and characterization of a novel small biologic alternative to proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies,DS-9001a,albumin binding domain-fused anticalin protein£ÛJ£Ý.J Pharmacol Exp Ther,2018,365(2):368-378.
£Û58£Ý¡¡KIM T Y,SEO H D,LEE J J,et al.A dimeric form of a small-sized protein binder exhibits enhanced anti-tumor activity through prolonged blood circulation£ÛJ£Ý.J Control Release,2018,279:282-291.
£Û59£Ý¡¡MITCHELL T,CHAO G,SITKOFF D,et al.Pharmacologic profile of the adnectin BMS-962476,a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering£ÛJ£Ý.J Pharmacol Exp Ther,2014,350(2):412-424.
£Û60£Ý¡¡STEIN E,TOTH P,BUTCHER M B,et al.Safety,tolerability and ldl-c reduction with a novel anti-pcsk9 recombinant fusion protein (lib003):results of a randomized,double-blind,placebo-controlled,phase 2 study£ÛJ£Ý.Atherosclerosis,2019,287:e7.
£Û61£Ý¡¡LANDLINGER C,POUWER M G,JUNO C,et al.The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol,vascular inflammation,and atherosclerosis in apoe 3 leiden.Cetp mice£ÛJ£Ý.Eur Heart J,2017,38(32):2499-2507.
£Û62£Ý¡¡CIVEIRA F,JARAUTA E,Vaccine against PCSK9:the natural strategy from passive to active immunization for the prevention of atherosclerosis£ÛJ£Ý.J Thorac Dis,2017,9(11):4291-4294.
£Û63£Ý¡¡WU D,ZHOU Y,PAN Y,et al.Vaccine against PCSK9 improved renal fibrosis by regulating fatty acid ¦Â-oxidation£ÛJ£Ý.J Am Heart Assoc,2020,9(1):e014358.
£Û64£Ý¡¡LINTNER N G,MCCLURE K F,PETERSEN D£¬et al.Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain£ÛJ£Ý.PLoS Biol,2017,15(3):e2001882.
£Û65£Ý¡¡PETERSEN D N,HAWKINS J,RUANGSIRILUK W,et al.A small-molecule anti-secretagogue of PCSK9 targets the 80S ribosome to inhibit PCSK9 protein translation£ÛJ£Ý.Cell Chem Biol,2016,23(11):1362-1371.
£Û66£Ý¡¡MCCLURE K F,PIOTROWSKI D W,PETERSEN D,et al.Liver-targeted small-molecule inhibitors of proprotein convertase subtilisin/kexin type 9 synthesis£ÛJ£Ý.Angew Chem Int Ed Engl,2017,56(51):16218-16222.
£Û67£Ý¡¡EVISON B J,PALMER J T,LAMBERT G,et al.A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove£ÛJ£Ý.Bioorg Med Chem,2020,28(6):115344.
£Û68£Ý¡¡WU C,XI C,TONG J,et al.Design,synthesis,and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia£ÛJ£Ý.Acta Pharm Sin B,2019,9(6):1216-1230.
£Û69£Ý¡¡GRAHAM M J,LEMONIDIS K M,WHIPPLE C P,et al.Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice£ÛJ£Ý.J Lipid Res,2007,48(4):763-767.
£Û70£Ý¡¡GUPTA N,FISKER N,ASSELIN M C,et al.A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo£ÛJ£Ý.PLoS One,2010,5(5):e10682.
£Û71£Ý¡¡VAN POELGEEST E P,HODGES M R,MOERLAND M,et al.Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9(PCSK9):a first-in-human randomized,placebo-controlled trial£ÛJ£Ý.Br J Clin Pharmacol,2015,80(6):1350-1361.
£Û72£Ý¡¡NORATA G D,BALLANTYNE C M,CATAPANO A L.New therapeutic principles in dyslipidaemia:focus on LDL and lp(a) lowering drugs£ÛJ£Ý.Eur Heart J,2013,34(24):1783-1789.
£Û73£Ý¡¡BAUMAN J,JEARAWIRIYAPAISARN N,KOLE R.Therapeutic potential of splice-switching oligonucleotides£ÛJ£Ý.Oligonucleotides,2009,19(1):1-13.
£Û74£Ý¡¡ROCHA C S,WIKLANDER O P,LARSSON L,et al.Rna therapeutics inactivate PCSK9 by inducing a unique intracellular retention form£ÛJ£Ý.J Mol Cell Cardiol,2015,82:186-193.
£Û75£Ý¡¡FITZGERALD K,FRANK-KAMENETSKY M,MANT T,et al.Phase i safety,pharmacokinetic,and pharmacodynamic results for ALN-PCS,a novel RNAi therapeutic for the treatment of hypercholesterolemia£ÛJ£Ý.Arterioscler Thromb Vasc Biol,2012,32(Suppl 1):A67.
£Û76£Ý¡¡DING Q,STRONG A,PATEL K M,et al.Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing£ÛJ£Ý.Circ Res,2014,115(5):488-492.
£Û77£Ý¡¡SU Z L,HANG P Z,HU J,et al.Aloe-emodin exerts cholestero-llowering effects by inhibiting proprotein convertase subtilisin/kexin type 9 in hyperlipidemic rats£ÛJ£Ý.Acta Pharmacol Sin,2020,41(8):1085-1092.
£Û78£Ý¡¡LI H,DONG B,PARK S W,et al.Hepatocyte nuclear factor 1¦Á plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine£ÛJ£Ý.J Biol Chem,2009,284(42):28885-28895.
£Û79£Ý¡¡HWANG J T,KIM H J,CHOI H K,et al.Butein synergizes with statin to upregulate low-density lipoprotein receptor through hnf1¦Á-mediated PCSK9 inhibition in HepG2 cells£ÛJ£Ý.J Med Food,2020,23(10):1102-1108.
£Û80£Ý¡¡WANG D,YANG X,CHEN Y,et al.Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression£ÛJ£Ý.J Bio Chem,2020,295(47):15870-15882.
£Û81£Ý¡¡CUI C J,JIN J L,GUO L N,et al.Beneficial impact of epigallocatechingallate on LDL-c through PCSK9/LDLR pathway by blocking HNF1¦Á and activating foxo3a£ÛJ£Ý.J Transl Med,2020,18(1):195.
£Û82£Ý¡¡CAMERON J,RANHEIM T,KULSETH M A,et al.Berberine decreases PCSK9 expression in HepG2 cells£ÛJ£Ý.Atherosclerosis,2008,201(2):266-273.
£Û83£Ý¡¡MBIKAY M,MAYNE J,SIROIS F,et al.Mice fed a high-cholesterol diet supplemented with quercetin-3-glucoside show attenuated hyperlipidemia and hyperinsulinemia associated with differential regulation of PCSK9 and LDLR in their liver and pancreas£ÛJ£Ý.Mol Nutr Food Res,2018,62(9):1700729.
£Û84£Ý¡¡TAI M H,CHEN P K,CHEN P Y,et al.Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells£ÛJ£Ý.Mol Nutr Food Res,2014,58(11):2133-2145.
£Û85£Ý¡¡ADORNI M P,ZIMETTI F,LUPO M G,et al.Naturally occurring PCSK9 inhibitors£ÛJ£Ý.Nutrients,2020,12(5):1440.